Send to

Choose Destination
Dermatol Surg. 2015 Jun;41(6):693-701. doi: 10.1097/DSS.0000000000000340.

Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.

Author information

*Carruthers Clinical Research, Vancouver, Canada; †Sadick Research Group, New York, New York; ‡Dr. Brandt Dermatology Associates, Coral Gables, Florida; §Hospital Do Servidor Publico Municipal, Sao Paulo, Brazil; ‖Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida; ¶Monash University, Clayton, Victoria, Australia; #Cannes Private Clinic, Cannes, France; **Niagara Falls Dermatology and Skin Care Center, Niagara Falls, Canada; ††Allergan, Inc., Irvine, California; ‡‡Peloton Advantage, Parsippany, New Jersey.



Little information exists on how facial aesthetic treatments are incorporated into aesthetic regimens.


Assess the evolution of facial aesthetic treatments in patients receiving long-term continuous onabotulinumtoxinA treatment.


This international retrospective chart review included patients with ≥5 years of continuous onabotulinumtoxinA treatments including ≥1 glabellar lines treatment/year. Charts were reviewed for facial areas treated, number of treatments, doses/treatment visit, concomitant aesthetic procedures, and onabotulinumtoxinA-related adverse events.


Data were collected from 5,112 onabotulinumtoxinA treatment sessions for 194 patients over an average of 9.1 years. Dosing was relatively stable over time; however, interinjection intervals increased. Glabellar lines' treatment temporally preceded crow's feet lines and forehead lines' treatment. A majority of patients (85%) also received treatment with fillers. Cumulative increases in onabotulinumtoxinA treatments occurred over time and by facial area corresponding with increases in treatments with injectable fillers, energy-based devices, and prescription topical creams. The longer the patients were treated, the younger they perceived themselves to look. Rates of adverse events were low.


OnabotulinumtoxinA treatment evolved over time, coinciding with growth of the facial aesthetics market. Additional treatment modalities were added as complements to onabotulinumtoxinA. Long-term continuous onabotulinumtoxinA injections are an important component of contemporary facial aesthetic treatment regimens.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center